Earnings call transcript: Harrow Health Q1 2026 results miss expectations By Investing.com

Harrow Health reported a sharp Q1 2026 earnings miss, with EPS of -$0.74 versus -$0.35 expected and revenue of $44.2 million versus $52.55 million expected; shares fell 24.06% after hours to $29.03. Management blamed an $8 million VEVYE gross-to-net issue tied to higher patient out-of-pocket costs, but reaffirmed full-year revenue guidance of $350 million-$365 million and expects sequential improvement starting in Q2. The call also highlighted product and commercial catalysts, including expanded sales forces, IHEEZO pricing improvements, and upcoming launches for BYOOVIZ and IOPIDINE.

Analysis

The market is treating this as a simple execution miss, but the more important signal is that Harrow’s reported quarter is mechanically worse than the underlying demand trend. The near-term damage is concentrated in gross-to-net and channel timing, which means the P&L reset is likely to be front-loaded into Q1/Q2 while the revenue base re-accelerates later in the year. That creates a classic asymmetry: headline numbers stay noisy, but the real swing factor is whether management can convert access wins into cleaner monetization without reintroducing patient affordability friction.

The second-order issue is competitive. If the company’s share gains in dry eye and procedural products are real, then the main beneficiaries of the current stumble are not obvious product peers but larger distributors and payer intermediaries that can extract more of the value chain through pricing mechanics. CVS is a marginal loser here because the episode exposes how coverage expansion can still destroy net revenue if the benefit design pushes patients into higher out-of-pocket behavior. IQV is neutral in the near term, but if Harrow’s field-force expansion and prescription tracking work as claimed, the dataset quality edge may improve and help management respond faster next time.

The contrarian setup is that consensus may be over-penalizing the quarter as if it were demand failure rather than a monetization miss. If Q2 comes in anywhere near the guided range, the stock could mean-revert sharply because the market has already de-rated Harrow for YTD weakness and is now near levels that imply little credibility in the second-half ramp. The risk is that the same coverage/patient-mix issue reappears or that new launches slip by a quarter, which would shift this from a temporary reset into a longer-duration multiple compression story.

Key Decisions for Investors

• Short-dated tactical long HROW into Q2 print only if management shows weekly VEVYE script stability and no further net-price leakage; upside is a sharp relief rally, but stop if Q2 channel commentary weakens. Time horizon: 2-6 weeks.
• For higher conviction, buy HROW Sep/Dec call spreads rather than common stock to express a second-half recovery while capping risk if the gross-to-net issue recurs. Best risk/reward is around 1:2 to 1:3 premium at current depressed sentiment.
• Pair trade: long HROW / short a basket of payer-sensitive healthcare names if the thesis is that Harrow’s issue is company-specific monetization, not demand deterioration. This isolates the rebound from broader reimbursement noise.
• Fade the post-earnings overshoot only if the stock reclaims the low-30s without Q2 evidence; otherwise keep exposure small. The stock can stay cheap longer than the guidance can stay credible.
• Avoid initiating new long CVS purely on this event; the second-order readthrough is limited, and the bigger takeaway is that coverage expansion can shift value away from pharma and toward patient cost-sharing structures rather than insurers capturing an obvious win.